Patent directory · USPTO A61K / A61P
Browse patents
Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.
Quick answer
NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.
Patent results
-
US 12331297
Coagulation factor V (F5) iRNA compositions and methods of use thereof
granted -
US 12331040
Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
granted -
US 12331132
Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses
granted -
US 12331130
DDR1 antibodies and uses thereof
granted -
US 12331293
Bispecific antisense oligonucleotides for dystrophin exon skipping
granted -
US 12331279
Systems for producing cellular immunotherapeutics and methods of use thereof
granted -
US 12331334
Modified urokinase-type plasminogen activator polypeptides and methods of use
granted -
US 12331105
Broadly neutralizing antibodies against HIV
granted -
US 12331109
Antigen binding molecule formats
granted -
US 12331110
Monoclonal antibodies against endotrophin and the use thereof
granted -
US 12331058
SHP2 and CDK4/6 dual-target inhibitory compound and pharmaceutical composition containing the same
granted -
US 12331078
Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same
granted -
US 12331107
Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody
granted -
US 12331124
ALK2 antibodies and methods of use thereof
granted -
US 12329825
Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject
granted -
US 12329827
Devices, compositions and related methods for accelerating and enhancing bone repair
granted -
US 12332245
Cancer biomarkers and methods of use thereof
granted -
US 12331056
SHP2 phosphatase inhibitors and methods of use thereof
granted -
TW 202523278
Antibody drug conjugate platforms
granted -
WO 2025121445
POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2
granted -
WO 2025120867
POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET ANTICORPS ANTI-VEGFR2
granted -
WO 2025120866
POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2
granted -
EP 4567715
ERZEUGUNG SYNTHETISCHER DARSTELLUNGEN
granted -
EP 4567716
ERZEUGUNG SYNTHETISCHER DARSTELLUNGEN
granted
Frequently asked questions
What patents are included in this directory?
We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.
How do I search for a patent?
Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.
How is this different from the patent intelligence dashboard?
The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.